The latest research has indicated that combining cGAS-STING pathway-targeted agents with other immunotherapeutic approaches, such as immune checkpoint inhibitors, may result in enhanced anti-tumour efficacy, further highlighting the potential of this pathway in personalized cancer therapies [23]. The gene discussed is STING1; the disease is cancer.